LOX-1 Ligand Detection for PMN-MDSC Isolation and Cancer Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for distinguishing polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) from polymorphonuclear neutrophils (PMNs) in biological samples are complex, time-consuming, and inaccurate, primarily due to the heterogeneity of PMN-MDSCs and the lack of distinct markers, which complicates understanding their biology and clinical significance in cancer.
Innovation Solution
A method involving contacting a biological sample with a ligand that specifically binds to LOX-1 on the surface of cells, allowing for the detection and isolation of PMN-MDSCs by forming complexes, thereby differentiating them from PMNs, and using a pharmaceutical composition to inhibit LOX-1 expression or ER stress in neutrophils to reduce PMN-MDSC accumulation in cancer patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If density gradient centrifugation is used to separate PMN-MDSC from PMN, then cell separation is achieved, but the method is complex, time-consuming, and inaccurate due to heterogeneity of PMN-MDSC and lack of distinct markers
Solution Approach 1:
The patent uses flow cytometry with fluorescently labeled antibodies that bind to specific surface markers (CD11b, CD14, CD15, CD66b, HLA-DR) on PMN-MDSCs. These markers create distinct fluorescence signals (color changes) that allow accurate identification and separation of PMN-MDSC from PMN, replacing the complex density gradient method with a marker-based fluorescent detection approach.
2Difficulty of detecting and measuring
If multiple gradient separation and multi-color flow cytometry are used to distinguish PMN-MDSC from PMN, then detection capability is improved, but the process becomes more complicated and difficult to standardize
Solution Approach 1:
The patent defines specific phenotypic parameter combinations (CD11b+CD14-CD15+CD66b+ with or without HLA-DR expression) to distinguish PMN-MDSC from PMN. By establishing clear parameter thresholds and marker expression patterns, the method becomes easier to standardize and reproduce across different laboratories, replacing the subjective and variable density gradient separation process.
3Quantity of substance
If density gradient centrifugation is used to separate PMN-MDSC, then cell isolation is achieved, but activated PMN without suppressive activity are also enriched, leading to heterogeneity
Solution Approach 1:
The patent extracts and isolates specific surface markers (CD11b, CD14, CD15, CD66b, HLA-DR) that are differentially expressed on PMN-MDSC versus activated PMN. By using antibodies against these markers in flow cytometry, the method selectively identifies and isolates true PMN-MDSC with suppressive activity, excluding activated PMN that lack the specific marker combination, thus improving population purity and reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate monitoring and isolation of PMN-MDSCs, facilitating differential diagnosis and treatment of cancer by correlating LOX-1+ cell numbers with tumor size and suppressing immune suppressive activity, thus potentially improving cancer treatment outcomes.
Implementation Method 1
contacting a biological sample with a ligand that specifically binds to LOX-1 on the surface of cells, allowing for the detection and isolation of PMN-MDSCs by forming complexes
Data Source
AI summary
A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described. A composition for use in diagnosing and treating cancer related to PMN-MDSC is provided that contains antagonists and/or inhibitors of genes related to the ER stress response.